Document:

<PAGE>

Exhibit 10.12

Business Loan Agreement dated as of November 30, 2000 by and between the Company
and Wells Fargo Bank, N.A.

BUSINESS LENDING CONFIRMATION LETTER
November 30, 2000

Thanksgiving Coffee Company, Inc.
P. O. Box 1918
Fort Bragg, CA 95437-1918

WELLS FARGO BANK, N.A. ("Bank"), agrees to make available to Thanksgiving
Coffee Company, Inc. ("Borrower") a PrimeLoan (the "Credit").  The Credit shall
bear interest and be repayable in accordance with the terms and conditions of
the Agreement.  The Agreement consists of (1) the Confirmation Letter ("this
Letter"), (2) the Business Lending Disclosure dated October 01, 1999 (the
"Disclosure") and (3) any Related Documents.  All terms and conditions of the
Disclosure and Related Documents are incorporated herein by reference for all
purposes.  All capitalized terms not defined in this Letter are defined in the
Disclosure.

Promise To Pay.  Borrower promises to pay to Bank, or order, the principal
amount of $464,000.00 together with interest on the unpaid principal balance.
Borrower will pay Bank at Bank's address shown in this letter or at such other
place as Bank may designate in writing.

Interest.  The interest rate applicable to this Credit is subject to change from
time to time based on changes in the Prime Rate. The Prime Rate currently is
9.500% per annum.  The interest rate to be applied to the unpaid principal
balance of Credit will be 3.000% above the Prime Rate resulting in an initial
rate of 12.500% per annum.

Interest Accrual Basis.  Interest shall be computed on a 365/360 simple interest
basis; that is, by multiplying the ratio of the annual interest rate over a year
of 360 days, times the outstanding principal balance, times the actual number of
days the principal is outstanding.

Payments.  The principal amount of this Credit shall be amortized over 60 months
and shall be payable in 59 equal monthly payments of $7,733.33.  In addition to
such principal payments, accrued unpaid interest shall be due and payable on
each payment due date.  These principal plus interest payments shall be payable
as follows:  If the loan disbursement occurs on or before the 24th day of any
month, the first payment due date shall be the 15th day of the next month; if
the loan disbursement occurs after the 24th day of any month, the first payment
due date shall be the 15th day of the second month following the disbursement.
Payments shall be due on the same day of each month thereafter until maturity of
the Credit, which is the 15th day of the 60 month following the first payment
due date, at which time all the remaining unpaid principal, accrued interest and
any other amounts owed in connection with Credit shall become due and payable in
full.

Automatic Debit of Payments.  Bank is authorized to automatically debit payments
and other amounts due and owing in connection with this Credit from Borrower's
Well Fargo Bank, N.A. account number 000000451028112.  This authorization shall
remain in full force and effect until written revocation from the Borrower or
Account Holder has been received and processed by WELLS FARGO BANK, N.A.
("Bank") at its business Lending office at Business Lending, 177 Park Center
Plaza MAC #A0514-011, San Jose, CA 95113.

Disbursement Information.  The estimated proceeds of the Credit shall be
disbursed as follows:

Collateral.  Subject to the terms and conditions of the Disclosure, as security
for the obligations set forth in Section 2.1 of the Disclosure, THANKSGIVING
COFFEE COMPANY, INC., as Grantor, pledges and grants to Bank a first priority
security interest in the following property, whether existing or hereafter
arising, now owned or hereafter acquired, and wherever located, and all Proceeds
of the foregoing (including insurance):

<PAGE>

Any property described in Exhibit(s)(if any) attached hereto and made part
hereof.

All accounts, inventory, equipment, instruments, general intangibles and
contract rights.

Fees.  Borrower shall pay estimated fees as follows:

Loan Fee             $2,500.00             From Account          000000451028112

Prepayment Terms.   Borrower may principal of the Credit at any time, in any
amount, without penalty.

Additional Provisions.  This document may be signed in any number of separate
copies, each of which shall be effective as an original, but all of which taken
together shall constitute a single document.  An electronic transmission or
other facsimile of this Letter or any signed document shall be deemed an
original and shall be admissible as evidence of the document and the signer's
execution.  The Agreement shall be governed by the laws of the state  of
California and applicable Federal Law.

Purpose.  The proceeds of the Credit shall be used primarily for business or
commercial purposes.

At the time the Agreement is signed and delivered to Bank, the persons signing
below, including without limitation the Borrower(s), any Grantor(s) and any
Guarantor(s), acknowledge receipt of the Agreement, including the Disclosure and
Related Documents, and accept all terms and conditions contained in them.
Unless a fully signed copy of this Letter and all Related Documents is received
by Bank within 30 days, this off to extend credit will expire.  This offer is
transferable or assignable, and may be withdrawn or modified at any time prior
to Bank's receipt of the above fully signed documents.

This Letter, the Disclosure, and any Related Documents represent the final
agreement between the parties and may not be contradicted by evidence of prior,
contemporaneous, or subsequent oral agreements of the parties.  There are no
unwritten oral agreements between the parties relating to this Credit.<PAGE>

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS,
HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                                                   Exhibit 10.12

                               THIRD AMENDMENT TO
                            COLLABORATION AGREEMENT

     This Third Amendment To Collaboration Agreement (this "Collaboration Third
Amendment") is made and entered into as of this 14th day of February, 2001 by
and between Sanwa Kagaku Kenkyusho Co., Ltd., a Japanese corporation ("Sanwa")
and Telik, Inc., a Delaware corporation ("Telik").

                                    Recitals
                                    --------

     A.  Sanwa and Telik are parties to that Collaboration Agreement dated as of
December 20, 1996 as amended by that certain First Amendment to Collaboration
Agreement dated September 24, 1997 and that Second Amendment to Collaboration
Agreement dated October 29, 1998 (the "Collaboration Agreement") pursuant to
which the Parties have jointly engaged in research to identify one or more
compounds which activate the insulin signal transduction pathway and appear to
be useful for treatment of diabetes mellitus or insulin resistance in humans.

     B.  Sanwa and Telik are entering into a Master Amendment Agreement of even
date herewith in connection with which, as one of the conditions to Sanwa paying
Telik the amount set forth therein, the parties have agreed to execute and
deliver this Collaboration Third Amendment.

     NOW, THEREFORE, in consideration of the above recitals and for other good
and valuable consideration, the adequacy and receipt of which are hereby
acknowledged, the parties hereby agree as follows:

     1.  Amendments.   The Collaboration Agreement is hereby amended as follows:
         -----------

         A.  Section 2.1 is amended in its entirety as follows:

             "The Parties will participate in a program (the "Research Program")
             to research and discover novel compounds in the Field. The Research
             Program shall commence on the Effective Date and continue until the
             fifth anniversary of the Effective Date, unless (i) terminated
             pursuant to Sections 9.2 or 9.3 or (ii) extended by mutual written
             agreement of the Parties. The period of time during which the
             Research Program is in effect shall be the "Research Term." The
             Research Term shall be conducted pursuant to a detailed research
             plan attached hereto as Exhibit A, which may be modified from time
             to time by the RMC (the "Research Plan"). Telik shall commence the
             Research Program promptly upon execution of this Agreement. Telik
             shall devote commercially reasonable efforts to its obligations
             under the Research Program, consistent with the efforts Telik
             devotes to Telik's own research programs of comparable market
             potential."

                                      1.
<PAGE>

         B.  Section 2.5.1 is amended in its entirety as follows:

             "Telik will be responsible for providing [*] (the [*] all
             infrastructure [*] necessary for conducting [*] Phase 1 of the
             Research Plan, relating to identification and selection of advanced
             lead compounds and Phase 2 of the Research Plan, relating to
             identification and selection of Clinical Candidates. Telik will
             also use commercially reasonable efforts to undertake the US FDA
             Phase 1 clinical studies or European equivalent with respect to or
             based on any compounds discovered as a result of the Research Plan.
             Telik, [*], will also be responsible for providing all
             infrastructure [*] necessary for and conducting [*], Phase 3 of the
             Research Plan, relating to all IND enabling work for Clinical
             Candidates, except that portion of Phase 3 work identified in the
             Research Plan as uniquely required for an IND application in Japan,
             for:

             (i)      The first Clinical Candidate; and

             (ii)     Subsequent Clinical Candidates if Telik shall choose by
                      written notice to Sanwa, to develop or have developed the
                      same Clinical Candidate(s) outside the Sanwa Territory.

             If, as of the date Telik provides notice to Sanwa pursuant to
             Section 2.5.1 (ii), Sanwa has commenced work on that portion of
             Phase 3 of the Research Plan for which Telik would be responsible
             as a result of providing such notice using protocols for such Phase
             3 work as may be recommended by the RMC, then Telik shall promptly
             [*] such portion of Phase 3 of the Research Plan and Telik shall
             take over and complete or have such work completed."

         C.  Section 2.7 is amended in its entirety to read as follows:

             "Sanwa will have the right, but no obligation, to provide
             infrastructure [*] necessary for and to conduct [*] that portion of
             Phase 3 of the Research Plan identified therein as uniquely
             required for an IND application in Japan with respect to Clinical
             Candidates."

         D.  Section 2.8.3 is revised to read in its entirety as follows:

             "2.8.3 Telik shall make available and disclose to Sanwa, on a
             quarterly basis, all work related to Phase 3 of the Research
             Program for which Telik is responsible pursuant to Section 2.5.
             Telik shall also make available to Sanwa all work related to and
             all results of any FDA, European or other clinical studies
             conducted based on any compounds discovered as a result of the
             Research Program, including, without limitation, any US FDA Phase 1
             clinical studies or equivalent foreign studies conducted by Telik.
             Telik shall also make available to Sanwa data within the Field
             relevant to
                                      2.

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.
<PAGE>

             the Research Program arising from arrangements between Telik and
             third parties similar to this Agreement but only to the extent, and
             upon such terms, as such third party shall agree including, if
             necessary, an agreement by Sanwa to provide similar information to
             such third party upon a reciprocal basis. Without limiting the
             generality of the foregoing, Telik agrees to use its reasonable
             efforts in good faith to cause any third party having rights to
             Clinical Candidates outside the Sanwa Territory to provide the
             results of tests and other work corresponding to Phase 3 of the
             Research Plan to Sanwa for such Clinical Candidates. The
             obligations of Telik set forth in this Section 2.8.3 shall
             terminate upon Telik's receipt of written notice from Sanwa
             pursuant to Section 4.4."

         E.  Section 2.8.4 is revised to read in its entirety as follows:

             "To the extent that Sanwa performs any Phase 3 work relating to
             Clinical Candidates, Sanwa shall disclose the results of such work
             to Telik. Telik may use such information solely for the purposes of
             the Research Program and shall not use it for any other purpose or
             disclose it to any third party unless Sanwa agrees to the terms of
             such use or disclosure (which may include [*] for all or a portion
             of the Phase 3 work conducted by Sanwa or on Sanwa's behalf by a
             third party)."

         F.  Sections 2.10(b) and 2.10(c) are deleted in their entirety and
             Section 2.10(d) is renumbered as Section 2.10 (b) and revised in
             its entirety to read as follows:

             "(b) During the Research Term, Telik shall be fully responsible for
             performing all work [*] (the [*] and ensuring that at all times
             Telik has [*] to fulfill all of its obligations in accordance with
             the Research Plan."

         G.  Section 4.4 is amended in its entirety to read as follows:

             4.4 Exclusive Collaboration. Each party to this Agreement covenants
             and agrees that the Research Program shall be its sole and
             exclusive activity within the Field in the Sanwa Territory during
             the term of this Agreement. Telik covenants and agrees that during
             the term of this Agreement, Telik will not license compounds to
             third parties in the Sanwa Territory where the development of such
             compounds is directed toward the Field. Notwithstanding the
             foregoing, if (a) Telik has not developed a detailed clinical plan
             in form and content reasonably satisfactory to the parties for
             clinical studies to be carried out with respect to [*] compounds
             discovered as a result of the Research Program by [*], (b) Telik
             has not commenced clinical studies in accordance with such clinical
             plan by [*], or (c) Telik fails to use commercially reasonable
             efforts to diligently develop compounds discovered as a result of
             the Research Program or abandons development of such compounds,
             then upon written notice from

                                      3.

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.
<PAGE>

             Sanwa to Telik, all of Sanwa's duties and obligations pursuant to
             this Section 4.4 shall immediately terminate.

         H.  Section 9.4 is amended in its entirety to read as follows:

             9.4 Accrued Rights; Surviving Obligations. Termination of this
             Agreement shall not affect any accrued rights of either Party. The
             terms of Section 2.8.3, Articles 3, 6, 8 and 10 of this Agreement
             shall survive termination of this Agreement. Except as set forth in
             the License Agreement, promptly after termination of this Agreement
             each Party shall return or dispose of any know-how of the other in
             accordance with the instructions of the other, including without
             limitation any compounds, assays or other biological or chemical
             materials.

     2.  Defined Terms; Incorporation. Unless otherwise expressly provided
         ----------------------------
herein, defined terms used in this Third Amendment shall have the same meaning
as set forth in the Collaboration Agreement, and all terms herein shall be
incorporated into the Collaboration Agreement. From and after the Third
Amendment Effective Date, all references to the "Collaboration Agreement" in all
other documents delivered in connection with the Collaboration Agreement shall
refer to the Collaboration Agreement, as amended hereby.

     3.  Counterparts: Facsimile. This Third Amendment may be executed in
         -----------------------
counterparts and by facsimile.

     4.  Effective Date. This Third Amendment shall be effective as of
         --------------
February 14, 2001 (the "Third Amendment Effective Date").

     IN WITNESS WHEREOF, the parties have executed this Collaboration Third
Amendment as of the date first set forth above.

TELIK, INC.                                  SANWA KAGAKU KENKYUSHO CO., LTD.

/s/ Michael M. Wick                          /s/ Keiji Tanimoto
---------------------------------            -----------------------------------
By: Michael M. Wick, M.D., Ph.D.             By: Keiji Tanimoto
Its: Chairman and CEO                        Its: President

                                      4.

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00022-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00022-of-00352.parquet"}]]